Trial reportBlood2014
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Trial report in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00298766 (An Open-Label Phase 1/2 Study of VELCADE for Injection in Subjects With Light-Chain), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label Phase 1/2 Study of VELCADE for Injection in Subjects With Light-Chain (AL)-Amyloidosis
Who cites it
19 citing papers in PubMed.
- Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis.Blood advances · 2022Trial
- A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.Leukemia · 2022Trial
- Trial
- A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.Blood · 2017Trial
- Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.International journal of hematology · 2017Trial
- Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation.Bone marrow transplantation · 2024Observational
- Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.Blood cancer journal · 2022Article
- [Local and systemic light chain amyloidosis in patients with rheumatic diseases].Zeitschrift fur Rheumatologie · 2020Review
- Noninvasive assessment of corneal alterations associated with monoclonal gammopathy.International journal of hematology · 2019Article
- Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.Journal of blood medicine · 2019Review
- Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis.American health & drug benefits · 2018Article
- European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.Leukemia · 2018Review
- Novel Therapies in Light Chain Amyloidosis.Kidney international reports · 2018Review
- The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018Article
- Light Chain Amyloidosis.Mediterranean journal of hematology and infectious diseases · 2018Review
- Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.Circulation · 2017Review
- Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.Scientific reports · 2017Article
- New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.Current heart failure reports · 2016Review
- AL Amyloidosis: Unfolding a Complex Disease.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CAN2007 was a phase 1/2 study of once- and twice-weekly single-agent bortezomib in relapsed primary systemic amyloid light chain amyloidosis (AL) amyloidosis. Seventy patients were treated, including 18 and 34 patients at the maximum planned doses on the once- and twice-weekly schedules. This prespecified final analysis provides mature response and long-term outcomes data after 3-year additional follow-up since the last report. In the once-weekly 1.6 mg/m(2) and twice-weekly 1.3 mg/m(2) bortezomib groups, final hematologic response rates were 68.8% and 66.7%; 80% of patients in each group sustained their response for ≥1 year. One-year progression-free rates were 72.2% and 76.8%. Median overall survival (OS) was 62.1 months and not reached; 4-year OS rates were 75.0% and 63.0%. Low baseline difference in κ/λ free light-chain level was associated with higher hematologic complete response rates and longer OS. At data cutoff, 40 (57%) patients had received subsequent therapy, including 19 (27%) retreated with bortezomib, 11 (58%) of whom achieved complete or partial hematologic responses. Four patients received prolonged bortezomib for between 3.5 and 5.6 years, with no new safety concerns, highlighting the feasibility of long-term therapy. Single-agent bortezomib produced durable hematologic responses and promising long-term OS in relapsed AL amyloidosis. This trial was registered at www.clinicaltrials.gov as #NCT00298766.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.